您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Cathepsin C-IN-5
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Cathepsin C-IN-5
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Cathepsin C-IN-5图片
CAS NO:2825567-97-1
包装与价格:
包装价格(元)
10mg电议
25mg电议
50mg电议

产品介绍
Cathepsin C-IN-5 (compound SF38) 是一种有效的、选择性的和具有口服活性的 组织蛋白酶 C 抑制剂,Cat C、Cat L、Cat S、Cat B、Cat K 的 IC50s 分别为 59.9 nM, 4.26 µM、>5 µM、>5 µM、>5 µM。Cathepsin C-IN-5 抑制骨髓和血液中的 Cat C 活性。Cathepsin C-IN-5 降低 NSP(中性粒细胞丝氨酸蛋白酶)的活化。Cathepsin C-IN-5 具有抗炎活性。
Cas No.2825567-97-1
分子式C21H17ClN6OS
分子量436.92
储存条件4°C, away from moisture and light
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Cathepsin C-IN-5 (compound SF38) is a potent, selective and orally activeCathepsin Cinhibitor withIC50s of 59.9 nM, 4.26 µM, >5 µM, >5 µM, >5 µM for Cat C, Cat L, Cat S, Cat B, Cat K, respectively. Cathepsin C-IN-5 inhibits the Cat C activity in bone marrow and blood. Cathepsin C-IN-5 decreases the activation of NSPs (neutrophil serine proteases). Cathepsin C-IN-5 shows anti-inflammatory activity[1].

Cathepsin C-IN-5 (compound SF38) shows inhibition in THP-1 and U937 cells with IC50s of 115.4, 70.2 nM, respectively[1].

Cathepsin C-IN-5 (1500 mg/kg) shows no significant weight loss or toxic reaction within 7 days after the administration in ICR mice[1].
Cathepsin C-IN-5 (10 mg/kg for p.o.; 2 mg/kg for i.v.) shows good bioavailability with F=42.07%[1].
Cathepsin C-IN-5 (2, 10, 50 mg/kg; p.o.) shows effective antiinflammatory activity and potential protective effect in an animal model of ALI[1].

Animal Model:C57BL/6 male mice (acute lung injury (ALI) mice model)[1]
Dosage:2, 10, 50 mg/kg (one hour after administration, received LPS (20 mg/kg))
Administration:P.o.
Result:Decreased the levels of proinflammatory cytokines (TNF-a, IL-6, and GM-CSF) and increased the the concentration of the anti-inflammatory cytokine (IL-10) in a dose-dependent manner.